Le Lézard
Classified in: Health, Business
Subjects: VEN, MAT

Halley Venture Partners LP, a San Francisco-based Venture Capital Firm Focusing on Cannabis Technology Companies, Has Announced an $8 Million Anchor Investment


SAN FRANCISCO, Feb. 12, 2019 /PRNewswire/ -- HALLEY Venture Partners LP (HALLEY Partners), a San Francisco-based venture capital firm focusing on cannabis-related technology companies, has announced an $8 million capital commitment from an East Coast-based single family office with decades of investment management experience. Concurrently, HALLEY Partners has closed HALLEY Venture Fund I (Fund I) to new investors.

Founded by Managing Director Steven J. Schuman in 2017, HALLEY Partners focuses primarily on early-stage technology companies that can help licensed cannabis businesses increase sales, create new products, reduce costs, comply with regulations, and discover the medical benefits of cannabis and hemp. HALLEY Partners aims to fund ancillary cannabis tech companies with experienced management teams and large addressable markets. 

"We started investigating the cannabis space in 2014 and made our first personal bets in 2016. We then formed Fund I in late 2017 and made a limited number of investments. HALLEY Partners has a significant amount of capital yet to be committed to specific portfolio companies and intends to add 10-15 more companies to its portfolios over the next 2-3 years."

HALLEY Partner's initial portfolio companies are Front Range Biosciences, springbig Inc, Bloom Automation, PathogenDx and FLRish Inc. 

While returns are a high priority, Schuman also believes that "cannabis participants should leave the industry in a better place than they found it." Accordingly, from the very inception of Fund I, HALLEY Partners has pledged to contribute at least 5% of the general partner profits to: (1) cannabis legalization efforts (2) non-profit medical research; and (3) reversing the damage of the 75+ year war on cannabis, especially for minority and lower income victims.

"With the close of Fund I, HALLEY Partners is poised to support unprecedented ancillary growth and become a stronghold in the ongoing cannabis revolution," continues Schuman. "There is not only a tremendous opportunity for investors in the marketplace, but also the prospects to drive technology developed in this space to adjacent agriculture and consumer industries."

Cannabis start-up companies that fit the above strategy are encouraged to contact HALLEY Partners via www.halleyvp.com.

About HALLEY Venture Partners LP

Founded by Managing Director Steven J. Schuman in 2017, HALLEY Venture Partners LP focuses primarily on early-stage technology companies that can help licensed cannabis businesses increase sales, create new products, reduce costs, comply with regulations and discover the medical benefits of cannabis and hemp. HALLEY Partners aims to fund ancillary cannabis tech companies with experienced management teams and large addressable markets. 

 

SOURCE HALLEY Venture Partners LP


These press releases may also interest you

at 10:21
Highlights of the Annual Results as of December 31, 2023: Revenue reached RMB2,155.6 millionGross profit amounted to RMB738.5 millionAdjusted non-IFRS net loss improved to RMB208.8 million, representing a significant turnaround from a negative...

at 10:17
The life insurance comparison site QuickQuote.com recently published a guide to accidental death and dismemberment (AD&D) insurance. It revealed that some plans cost only $4 a month and provide $100,000 in coverage....

at 10:15
Options Medical Weight Losstm, the nation's premier medical weight loss clinic and provider of medical weight loss solutions, is proud to announce its second clinic in the Metro Atlanta area at 3651 Peachtree Parkway, Suite B. The clinic cordially...

at 10:15
The "MRSA Drugs Market by MRSA Type, Drug Class, Disease Indication, Route of Administration, Distribution Channel, and Region 2024-2032" report has been added to ResearchAndMarkets.com's offering. The global MRSA drugs market size reached US$ 3.8...

at 10:15
Chartis, a comprehensive healthcare advisory firm, today announced that its line of business focused on helping medical staff services departments (MSSDs) transform to elevate performance will restore its former name?Greeley, A Chartis Company. It...

at 10:10
Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology and immunology, released annual...



News published on and distributed by: